logo
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

Globe and Mail31-07-2025
RESEARCH TRIANGLE PARK, N.C., July 31, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that its president and chief executive officer, Jon Stonehouse, has informed the board of directors of his intention to retire on December 31, 2025. The board has appointed Charlie Gayer, currently the company's chief commercial officer (CCO), as the company's next president, effective August 1, 2025, and next chief executive officer, effective January 1, 2026.
Mr. Stonehouse will continue to serve on the board of directors and Mr. Gayer will join the company's board, effective January 1, 2026.
Mr. Gayer has built and led the commercial organization responsible for the successful launch of ORLADEYO ® (berotralstat), bringing the first oral prophylactic therapy to people with hereditary angioedema and driving exceptional revenue growth, with expected peak sales of $1 billion. He also has played a pivotal role in shaping the company's recent business development strategy, including the planned sale of its European operations.
'We want to thank Jon for building BioCryst into the commercial, profitable company it is today, with such a bright future,' said Nancy Hutson, chair of the board. 'As part of our succession planning process, we have evaluated outstanding internal and external potential successors and Charlie stood out in that process, with an ability to build on the success he has achieved with ORLADEYO to further deliver on our mission to bring life-changing therapies to patients and create long-term value for our stakeholders.'
'I am delighted to hand the leadership responsibility of the company to Charlie. He has a proven track record of delivering results and is largely responsible for one of the best commercial launches of a rare disease drug in recent history. Charlie is a purpose-driven leader who understands our company's mission to serve patients living with rare diseases in extraordinary ways,' said Stonehouse. 'I am thrilled the board chose Charlie, as he understands we have worked hard to build a special culture at BioCryst that we believe has a direct impact on the company's performance in creating value. He is the perfect leader to take the company even further.'
'I am grateful for Jon's leadership and the patients-first culture he has fostered over my 10 years at BioCryst. Under his guidance, BioCryst has matured to the point where it is generating significantly increasing cash resources through ORLADEYO revenue while also advancing a promising pipeline. This is an exciting time for the company and I am deeply honored that the board has entrusted me to lead BioCryst into its next chapter," said Gayer.
Mr. Gayer was promoted to CCO in January 2020, after joining the company in 2015 as vice president of global strategic marketing. Prior to BioCryst, he held U.S. and global commercial leadership roles in competitive rare disease categories at Talecris Biotherapeutics, Inc. and led U.S. alpha-1 antitrypsin deficiency marketing, and later European sales and marketing. After Grifols, S.A. acquired Talecris in 2011, he led the U.S. marketing team for the combined immune globulin portfolio of the two companies. Prior to joining Talecris, Mr. Gayer spent six years at GlaxoSmithKline in a range of professional marketing, consumer marketing and sales roles. He began his career as a strategic consultant for biopharmaceutical companies and spent three years as a business analyst at Genzyme Corporation. Mr. Gayer received his B.A. in politics from Princeton University and his M.B.A from the Fuqua School of Business of Duke University.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding future results, performance, achievements, plans and expectations regarding BioCryst's growth, pipeline, and value creation, BioCryst's expectations with respect to the transition of the CEO role, and statements related to the anticipated sale of BioCryst's European ORLADEYO business. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: BioCryst's ability to successfully implement or maintain its commercialization plans for ORLADEYO; BioCryst's ability to successfully progress its pipeline development plans; the commercial viability of ORLADEYO, including its ability to achieve sustained market acceptance and demand; ongoing and future preclinical and clinical development of product candidates may take longer than expected and may not have positive results; the FDA or other applicable regulatory agency may require additional studies beyond the studies planned for products and product candidates, may not provide regulatory clearances which may result in delay of planned clinical trials, may not review regulatory filings on our expected timeline, may impose certain restrictions, warnings, or other requirements on products and product candidates, may impose a clinical hold with respect to product candidates, or may withhold, delay or withdraw market approval for products and product candidates; product candidates, if approved, may not achieve market acceptance; BioCryst's ability to successfully commercialize its products and product candidates; BioCryst's ability to successfully manage its growth and compete effectively; timing for achieving and sustainability of profitability and positive cash flow may not meet management's expectations; statements regarding financial goals and the attainment of such goals may differ from actual results based on market factors and BioCryst's ability to execute its operational, capital deployment and budget plans; actual financial results may not be consistent with expectations, including that revenue, operating expenses and cash usage may not be within management's expected ranges; and BioCryst's completion of the planned sale of its European operations on anticipated terms and timing, including obtaining required regulatory approvals. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, which identify important factors that could cause actual results to differ materially from those contained in BioCryst's projections and forward-looking statements.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

IFF Launches POWERFRESH® ACE 2000, a Bread Fresh-Keeping Solution That 'Aces' the Shelf-Life Test
IFF Launches POWERFRESH® ACE 2000, a Bread Fresh-Keeping Solution That 'Aces' the Shelf-Life Test

National Post

time10 minutes ago

  • National Post

IFF Launches POWERFRESH® ACE 2000, a Bread Fresh-Keeping Solution That 'Aces' the Shelf-Life Test

Article content New enzyme solution delivers longer-lasting softness, operational efficiency and market-driven innovation tailored to U.S. bakery needs Article content NEW YORK — IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announces the launch of POWERFRESH® ACE 2000 to the U.S. market. This next-generation fresh-keeping enzyme solution is designed to help industrial bakeries deliver bread with improved softness, resilience and cohesiveness throughout shelf life — meeting specific consumer demands while improving operational efficiency. Article content Article content 'Developed by IFF's biosciences experts, this advancement underscores our commitment to helping bakeries deliver exceptional value and maintain a competitive edge in the industry,' said Clementina Dellomonaco, senior vice president of food biosciences at IFF. 'Whenever we enhance the consumer experience, we help our customers build stronger brand equity, drive repeat purchases and unlock long-term growth.' As ingredient prices rise and consumer expectations for long-lasting freshness continue to grow, U.S. bakeries face unprecedented pressure to maintain product quality without increasing operational strain. A recent survey shows that 60% of U.S. consumers would buy bread marketed as 'fresher for longer,' and more than half expect at least four days of freshness at purchase. 1 POWERFRESH® ACE 2000 addresses these priorities by improving softness and resilience for up to 34 days, while reducing waste and inventory complexity. Article content In IFF-led trials, POWERFRESH® ACE 2000 demonstrated a strong performance across both white and whole-wheat bread applications. This enzyme consistently delivered superior resilience while maintaining structure and visual appeal, even at lower dosage levels compared to market alternatives, resulting in stable loaves with excellent texture and mouthfeel. Crucially, it preserved the soft, yet easy-to-butter texture that consumers prefer, even several days after purchase. Article content 'As a staple food, bread is a regular fixture in consumers' baskets — so expectations for quality are high and constant,' said Emily Wagener, industry leader for food and beverage enzymes for North America at IFF. 'At the same time, bakeries face challenges that require smarter solutions. POWERFRESH® ACE 2000 is bakers' ally to deliver high-quality products with the delicious texture and freshness consumers expect, every time.' Article content As the latest addition to IFF's established POWERFRESH® portfolio, this new solution offers a smarter path to consistent bread quality and efficiency — whether used in new formulations or to optimize existing ones. Improved product resilience enables industrial bakeries to extend distribution and better manage shelf-life targets. These operational gains also align with sustainability goals by reducing waste, minimizing returns and optimizing resources across the supply chain. Article content Learn more about POWERFRESH® ACE 2000 and IFF's innovative bakery enzyme portfolio here. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products — advancing wellness, delighting the senses and enhancing the human experience. Learn more at LinkedIn, Instagram and Facebook. Article content Article content Article content Article content

KUBRA Named One of Arizona's Most Admired Companies for 2025
KUBRA Named One of Arizona's Most Admired Companies for 2025

National Post

time10 minutes ago

  • National Post

KUBRA Named One of Arizona's Most Admired Companies for 2025

Article content TEMPE, Ariz. — KUBRA, a leading provider of customer experience management solutions for some of the largest utility, government, and insurance entities, is thrilled to announce that it was selected as one of Arizona's Most Admired Companies in 2025. Article content This honor, presented in partnership with AZ Big Media and BestCompaniesAZ, recognizes companies that set the standard across five pillars of excellence: customer opinion, innovation, leadership excellence, corporate and social responsibility, and workplace culture. With a record number of nominations and a highly selective judging process, this recognition highlights KUBRA's continued leadership and impact in Arizona's business community. Article content 'Being recognized for the fifth consecutive year is not just an achievement, it's a reflection of our team's daily commitment,' said Rick Watkin, President and CEO of KUBRA. 'We remain focused on cultivating a culture of innovation, inclusion, and service, and we're honored that our efforts are being celebrated once again in Arizona.' Article content KUBRA's success is driven by its dynamic, employee-centered culture that encourages collaboration, technological advancement, and social responsibility. Rather than just a place to work, KUBRA fosters a purpose-driven community where individuals are empowered to make a meaningful impact. Article content For prospective employees seeking opportunities at KUBRA, visit our careers page to explore openings and discover how you can join a team that values innovation, diversity, and growth. Article content About KUBRA Article content KUBRA provides customer experience management solutions to some of the largest utility, government, and insurance entities across North America. Our extensive portfolio includes billing and payments, mapping, mobile apps, proactive communications, and artificial intelligence solutions for customers. With more than two billion customer interactions annually, KUBRA services reach over 40% of households in the U.S. and Canada. KUBRA is an operating subsidiary of the Hearst Corporation. Visit for more information. Article content About Most Admired Companies Article content Arizona's Most Admired Companies is a business awards program designed to recognize the contributions and impact all Arizona employers bring to the state. Based on five pillars, this is the most comprehensive and prestigious company-based business award program in Arizona. Article content About BestCompaniesAZ Article content Founded in 2002, BestCompaniesAZ pioneered the intersection of recruiting, human resources, marketing, and public relations — today known as Employer Branding or 'PR for HR.' BestCompaniesAZ has evolved into an exclusive, niche marketing and employer branding firm that specializes in helping award-winning companies amplify their employer brand, expand their network, improve their reach, and attract top talent on a regional and national level. Visit the KUBRA profile to learn To learn more, visit KUBRA's profile on BestCompaniesAZ. Article content Article content Article content Article content Contacts Article content Media: Article content Article content Article content Article content

World oil market looks more ‘bloated' after OPEC+ hike, IEA says
World oil market looks more ‘bloated' after OPEC+ hike, IEA says

CTV News

time10 minutes ago

  • CTV News

World oil market looks more ‘bloated' after OPEC+ hike, IEA says

The sun begins to set behind crude oil tanks and a pumpjack, July 5, 2022, in Midland, Texas. The IEA's annual world energy outlook, which analyzes the global picture of energy supply and demand, was released Tuesday, Oct. 24, 2023. (Eli Hartman/Odessa American via AP, File) World oil supply will rise more rapidly than expected this year and next as OPEC+ members further increase output and supply from outside the group grows, the International Energy Agency said on Wednesday. Supply will rise by 2.5 million barrels per day (bpd) in 2025, up from 2.1 million bpd previously forecast, the IEA, which advises industrialized countries, said in a monthly report, and by a further 1.9 million bpd next year. OPEC+ is adding more crude to the market after the Organization of the Petroleum Exporting Countries, Russia and other allies decided to unwind its most recent layer of output cuts more rapidly than earlier scheduled. The extra supply, along with concern about the economic impact of U.S. President Donald Trump's tariffs, has weighed on oil this year. Supply is rising far faster than demand in the IEA's view. It expects world oil demand to rise by 680,000 bpd this year and 700,000 bpd next year, both down 20,000 bpd from the previous forecast. 'The latest data show lackluster demand across the major economies and, with consumer confidence still depressed, a sharp rebound appears remote,' the agency said in the report that linked its higher output forecast to increased OPEC+ production targets. 'Oil market balances look ever more bloated.' IEA demand forecasts are at the lower end of the industry range, as the agency expects a faster transition to renewable energy sources than some other forecasters. OPEC on Tuesday maintained its forecast for demand to rise by 1.29 million bpd this year - almost double the IEA figure. Oil prices LCOc1 extended losses after the IEA published its report at 0800 GMT, with Brent crude trading lower than US$66 a barrel. Implied surplus to rise The report implies that supply may exceed demand by almost 3 million bpd next year, driven by growth from outside the wider OPEC+ group and a limited expansion in demand. Despite higher OPEC+ production, non-OPEC producers will continue to lead supply growth this year and next owing to rising output in the U.S., Canada, Brazil and Guyana, according to the IEA. Still, additional sanctions on Russia and Iran may curb supplies from the world's third and fifth largest producers, the IEA said. The U.S. announced new sanctions on Iran last month and the European Union lowered a price cap for Russian oil as part of its latest sanctions on Moscow. 'It is clear that something will have to give for the market to balance,' the IEA said. Continued Chinese stockbuilding due to major institutional and policy developments aimed at enhancing energy security may help absorb the surplus, the agency said. This helped support prices earlier in the year, analysts have said. Despite lowering its demand forecast, the IEA expects global crude oil refining rates to approach a fresh all-time high of 85.6 million bpd in August, after reaching 84.9 million bpd in July. Global refinery runs will rise by 670,000 bpd to 83.6 million bpd in 2025 and by a further 470,000 bpd to 84 million bpd in 2026, driven by better than expected data for market economies grouped in the Organisation for Economic Co-operation and Development (OECD) and China, the agency said. (Reporting by Enes Tunagur. Editing by Alex Lawler, Bernadette Baum and Tomasz Janowski)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store